Neumora holder plans Rule 144 sale of 9,819 shares

Neumora Therapeutics, Inc. has a planned sale notice under Rule 144 covering 9,819 shares of common stock.

Rhea-AI Filing Summary

Neumora Therapeutics, Inc. has a planned sale notice under Rule 144 covering 9,819 shares of common stock. The shares are to be sold through Merrill Lynch on NASDAQ, with an aggregate market value of $34,458.98 and an approximate sale date of February 17, 2026.

The securities were acquired on February 14, 2026 through the vesting of a restricted stock unit award granted as part of the issuer’s equity compensation plan.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Neumora Therapeutics (NMRA) disclose in this Form 144?

The filing shows a planned sale of 9,819 shares of Neumora Therapeutics common stock under Rule 144. These shares are to be sold on NASDAQ through Merrill Lynch, with an aggregate market value of $34,458.98 and an approximate sale date of February 17, 2026.

How many Neumora Therapeutics (NMRA) shares are planned to be sold and on which exchange?

The notice covers 9,819 shares of Neumora Therapeutics common stock to be sold on NASDAQ. Merrill Lynch is listed as the broker, and the aggregate market value for this planned transaction is $34,458.98 based on the figures in the filing.

How were the Neumora Therapeutics (NMRA) shares in this Form 144 acquired?

The 9,819 common shares were acquired on February 14, 2026 through the vesting of a restricted stock unit award. The filing states this award was granted as part of Neumora Therapeutics, Inc.’s equity compensation plan, and the same date is given for acquisition and payment.

Which broker is handling the planned Neumora Therapeutics (NMRA) Rule 144 sale?

Merrill Lynch is listed as the broker for the Rule 144 sale of Neumora Therapeutics shares. The address provided is 225 Liberty Street, Floor 37, New York, NY 10281, and the transaction is designated for execution on the NASDAQ exchange according to the filing table.

What is the aggregate market value of the Neumora (NMRA) shares in this planned Rule 144 sale?

The aggregate market value of the 9,819 Neumora Therapeutics common shares covered by this notice is $34,458.98. This figure comes directly from the securities information table, which also lists the total shares, broker, exchange, and approximate sale date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 04:24 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001202769
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Neumora Therapeutics, Inc.
SEC File Number	001-41802
Address of Issuer	260 ARSENAL PLACE, SUITE 1 WATERTOWN MASSACHUSETTS 02472
Phone	(857) 760-0900
Name of Person for Whose Account the Securities are To Be Sold	BERNS PAUL L
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty Street Floor 37 New York NY 10281	9819	34458.98	167089114	02/17/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/14/2026	Vesting of restricted stock unit award	Neumora Therapeutics, Inc.			9819	02/14/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	02/17/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Paul Berns
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)